Payment overview · 2025
General Payments
$3,046.20
37 reported records · 11 companies
Healthcare provider profile · identity verified
Uri Guefen, M.D.
Allopathic & Osteopathic Physicians|General Practice · CHULA VISTA, CA · NPI 1275646333
Verified facts
What the public records show
CMS Open Payments records show Uri Guefen, M.D. received $3,046.20 in general payments during 2025 across 37 reported records.
ABBVIE INC. accounted for 57.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $1,738.85 | 57.1% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $298.06 | 9.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $232.07 | 7.6% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $192.96 | 6.3% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $173.44 | 5.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $114.37 | 3.8% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $76.83 | 2.5% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $74.65 | 2.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.96 | 2.3% | 3 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $57.46 | 1.9% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $18.55 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,796.20 | 36 |
| Consulting Fee | $1,250.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $1,738.85 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $245.23 | 4 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $223.13 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $156.57 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $124.25 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $114.37 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $107.82 | 5 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $102.03 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $76.83 | 3 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $74.93 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $74.65 | 4 | 2025 |
Source payment records
|
|||||
| ENSITE Normalized: ensite |
Device | Abbott Laboratories | $71.41 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $57.46 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.31 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $39.66 | 2 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 137 | 45 |
| Metformin Hcl Er | Metformin Hcl | 57 | 16 |
| Metformin Hcl | Metformin Hcl | 56 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 51 | 11 |
| Amlodipine Besylate | Amlodipine Besylate | 49 | 15 |
| Repatha Sureclick | Evolocumab | 49 | 11 |
| Losartan Potassium | Losartan Potassium | 43 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | 13 |
| Lisinopril | Lisinopril | 39 | 13 |
| Ozempic | Semaglutide | 39 | suppressed |
| Famotidine | Famotidine | 37 | 13 |
| Simvastatin | Simvastatin | 37 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | 11 |
| Levothyroxine Sodium | Levothyroxine Sodium | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 27 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | suppressed |
| Omeprazole | Omeprazole | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Gabapentin | Gabapentin | 23 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 20 | suppressed |
| Repatha Syringe | Evolocumab | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Furosemide | Furosemide | 11 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Repatha Pushtronex | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,046.20 · 37 records | ABBVIE INC. | AIRSUPRA, APRETUDE, APTIMA, BREZTRI, CREON, ENSITE, EVENITY, Extended Holter, FARAPULSE, FARXIGA, General - Therapies, JOT DX, LEQVIO, LINZESS, MOUNJARO, OTEZLA, REPATHA, Saxenda, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error